share_log

Canaccord Genuity Initiates Coverage On Moderna With Hold Rating, Announces Price Target of $82

Canaccord Genuity Initiates Coverage On Moderna With Hold Rating, Announces Price Target of $82

Canaccord Genuity以持有评级启动对Moderna的报道,宣布目标股价为82美元
Benzinga ·  2023/11/29 05:16

Canaccord Genuity analyst Bill Maughan initiates coverage on Moderna (NASDAQ:MRNA) with a Hold rating and announces Price Target of $82.

Canaccord Genuity分析师比尔·莫恩以持有评级开始对Moderna(纳斯达克股票代码:MRNA)进行报道,并宣布目标股价为82美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发